BioScrip Reports Third Quarter 2016 Financial Results

Go back to BioScrip Reports Third Quarter 2016 Financial Results

Jefferies Resumes BioScrip (BIOS) at Buy

November 8, 2016 7:22 AM UTC

Jefferies resumes coverage on BioScrip (NASDAQ: BIOS) with a Buy rating and a price target of $2.50.

Analyst Brian Tanquilut commented, "We were surprised by BIOS's disappointing Q3 and the resulting guidance cut, and recognize that it further dents the company's already-weak credibility... More

BioScrip (BIOS) Misses Q3 EPS by 7c

November 7, 2016 5:19 PM UTC

BioScrip (NASDAQ: BIOS) reported Q3 EPS of ($0.12), $0.07 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $224.5 million versus the consensus estimate of $223.26 million.

The Company reconfirms its plan to achieve between $14 million to $17 million in Home Solutions cost synergies... More